May 28 (Reuters) - Exact Sciences Corp EXAS.O:
EXACT SCIENCES ANNOUNCES EXPANDED CLINICAL VALIDATION OF THE ONCODETECT™ TEST AND MOLECULAR RESIDUAL DISEASE INNOVATION ROADMAP
EXACT SCIENCES CORP - NEXT-GENERATION ONCODETECT TEST AVAILABLE IN 2026
Source text: ID:nBw2bKKgma
Further company coverage: EXAS.O
((Reuters.Briefs@thomsonreuters.com;))